Nivolumab With PD-L1/IDO Peptide Vaccine Shows Efficacy in Metastatic Melanoma

Source: Targeted Oncology, April 2022

Encouraging efficacy and survival has been observed in an early-phase study of nivolumab (Opdivo) combined with a PD-L1/IDO peptide vaccine in patients with metastatic melanoma, according to data from a phase 1/2 trial (NCT03047928) presented at the AACR Annual Meeting 2022.1

At the December 1, 2021, data cutoff date, updated results from the trial showed that among 30 efficacy evaluable patients the overall response rate (ORR) was 80%, and 47% of patients achieved a complete response (CR). At a median follow-up of 2.7 years, the median progression-free survival (PFS) was 25.3 months, and the median overall survival (OS) was not reached.

The trial enrolled patients with stage IV melanoma who had not been previously treated with an anti-PD-1 therapy. Patients received the anti-PD-1 antibody nivolumab at a dose of 3 mg/kg every 2 weeks for up to 2 years. Investigators administered the IDO/PD-L1 peptide vaccine subcutaneously for up to 15 doses: 1 dose every 2 weeks for a total of 6 doses and 1 dose every 4 weeks for a total of 9 doses. Responding patients stayed on nivolumab at a dose of 6 mg/kg administered every 4 weeks after the vaccine series was completed.